Wishlist: SOMAscan analysis of plasma samples from breast cancer patients
Type: Forecast
Overview
Description
Cardiotoxicity biomarker analysis of plasma samples from breast cancer patients treated with doxorubicin
Est. Value
Min: $25,000
Max: $250,000
Max: $250,000
Est. Award Date
27-Jun
Future Opp
Source Est. Solicitation Date
27-May
Set Aside
Full and Open
Procurement Method
Full and Open
Place of Performance
USA
Forecast Source
Department of Health and Human Services
Food and Drug Administration is forecasted to issue a procurement for Wishlist: SOMAscan analysis of plasma samples from breast cancer patients around 27-Jun worth up to $250,000.
Agency
Source Level 1 Agency
Department of Health and Human Services
Source Level 2 Agency
FDA
Contacts
Potential Bidders and Partners
Similar Active Opportunities
Additional Detail
Date Published
11/6/26
Date Modified
11/7/26
Additional Notes
Program Office: 75F401; Contracting Office: 75F402